BeiGene, Ltd.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$306.2M
Doctors Paid
363
Transactions
24,336
2024 Total
$76.9M
Payment Breakdown by Category
Research$304.2M (99.3%)
Consulting$2.1M (0.7%)
Travel$257.57 (0.0%)
Food & Beverage$154.02 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $304.2M | 23,790 | 99.3% |
| Consulting Fee | $2.1M | 543 | 0.7% |
| Travel and Lodging | $257.57 | 1 | 0.0% |
| Food and Beverage | $154.02 | 2 | 0.0% |
Payments by Type
Research
$304.2M
23,789 transactions
General
$2.1M
546 transactions
Ownership
$0
1 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | $45.0M | 1 | 3,053 |
| A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib | $42.2M | 0 | 1,498 |
| An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) | $23.1M | 0 | 887 |
| An Open-label, Multi-center, Monotherapy, Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies | $18.7M | 0 | 443 |
| A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib | $17.6M | 0 | 902 |
| An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | $16.4M | 0 | 569 |
| A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | $14.8M | 0 | 580 |
| A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies | $12.6M | 0 | 179 |
| A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | $10.4M | 0 | 1,778 |
| A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | $10.1M | 0 | 169 |
| A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients Wi | $10.0M | 0 | 561 |
| An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies | $7.9M | 0 | 567 |
| A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | $7.5M | 0 | 108 |
| Phase 3 Randomized, Open -Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | $4.7M | 0 | 197 |
| A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | $4.7M | 0 | 383 |
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients With Mild-to-Moderate COVID-19 | $3.8M | 0 | 135 |
| A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenstrom's Macroglobulinemia (WM) | $3.0M | 5 | 198 |
| Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | $3.0M | 0 | 1,043 |
| A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) | $2.3M | 0 | 498 |
| A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | $2.2M | 0 | 284 |
| AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) | $2.2M | 0 | 702 |
| A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies | $1.9M | 0 | 336 |
| A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID 19 Infection and Pulmonary Distress | $1.9M | 0 | 41 |
| A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) | $1.8M | 0 | 326 |
| A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors | $1.8M | 0 | 42 |
| Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer | $1.6M | 0 | 392 |
| A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | $1.6M | 0 | 528 |
| Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors | $1.5M | 0 | 450 |
| A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B Cell Malignancies | $1.5M | 0 | 266 |
| A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | $1.5M | 0 | 759 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Internal Medicine | $1.0M | 61 | $16,866 |
| Hematology & Oncology | $533,459 | 180 | $2,964 |
| Medical Oncology | $183,728 | 54 | $3,402 |
| Hematology | $72,196 | 23 | $3,139 |
| Pediatric Hematology-Oncology | $17,000 | 1 | $17,000 |
| Specialist | $11,091 | 7 | $1,584 |
| Acute Care | $11,040 | 2 | $5,520 |
| Diagnostic Radiology | $10,405 | 7 | $1,486 |
| Orthopaedic Surgery | $9,100 | 2 | $4,550 |
| Student in an Organized Health Care Education/Training Program | $8,100 | 5 | $1,620 |
| Gastroenterology | $5,482 | 2 | $2,741 |
| Neurology | $4,500 | 1 | $4,500 |
| Family | $2,080 | 2 | $1,040 |
| Nurse Practitioner | $2,080 | 2 | $1,040 |
| Physician Assistant | $2,080 | 2 | $1,040 |
| Vascular & Interventional Radiology | $1,881 | 1 | $1,881 |
| Emergency Medicine | $1,458 | 1 | $1,458 |
| Dermatology | $1,200 | 1 | $1,200 |
| Infectious Disease | $1,100 | 1 | $1,100 |
| Adult Health | $1,040 | 1 | $1,040 |
| Oncology | $1,040 | 1 | $1,040 |
| Epilepsy | $887.50 | 1 | $887.50 |
| Rheumatology | $620.00 | 1 | $620.00 |
| Geriatric Medicine | $525.00 | 1 | $525.00 |
| Hospice and Palliative Medicine | $450.00 | 1 | $450.00 |
Top Paid Doctors — Page 15
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Sunil Babu, M.d, M.D | Hematology & Oncology | Fort Wayne, IN | $450.00 | $0 |
| Michael Hemphill, Md, MD | Hematology & Oncology | Hermitage, TN | $450.00 | $0 |
| Dr. Alkarim Tajuddin, M.d, M.D | Hematology & Oncology | Elk Grove Village, IL | $450.00 | $0 |
| Dr. Branden Hsu, M.d, M.D | Hematology & Oncology | Houston, TX | $450.00 | $0 |
| Mark Knapp, Md, MD | Medical Oncology | Columbus, OH | $450.00 | $0 |
| Dr. Mike Cusnir, M.d, M.D | Specialist | Miami Beach, FL | $450.00 | $0 |
| Michael Wertheim, Md, MD | Hematology & Oncology | Fort Myers, FL | $450.00 | $0 |
| Thomas Ratliff, Md, MD | Hematology & Oncology | Germantown, TN | $416.67 | $0 |
| Michael Morse, M.d, M.D | Hematology & Oncology | Durham, NC | $375.00 | $0 |
| Pierre Gholam, Md, MD | Gastroenterology | Cleveland, OH | $350.00 | $0 |
| Hayder Saeed, M.d, M.D | Hematology & Oncology | Tampa, FL | $300.00 | $0 |
| Evan Chen, Md, MD | Medical Oncology | Boston, MA | $280.00 | $0 |
| Dr. Shital Makim, Md, MD | Diagnostic Radiology | Boston, MA | $100.00 | $0 |
About BeiGene, Ltd.
BeiGene, Ltd. has made $306.2M in payments to 363 healthcare providers, recorded across 24,336 transactions in the CMS Open Payments database. In 2024, the company paid $76.9M. The top product by payment volume is BRUKINSA ($240.5M).
Payments were distributed across 25 medical specialties. The top specialty by payment amount is Internal Medicine ($1.0M to 61 doctors).
Payment categories include: Food & Beverage ($154.02), Consulting ($2.1M), Research ($304.2M), Travel & Lodging ($257.57).
BeiGene, Ltd. is associated with 2 products in the CMS Open Payments database.